Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
Medicenna Therapeutics (OTCQX: MDNAF) has strengthened its intellectual property portfolio with five newly granted patents for its IL-2 and IL-4 Superkine platforms. The patents, which expire between 2033 and 2040, cover composition, formulation, combination, use, and therapeutic applications across major global markets.
Key patents include protection for MDNA11 in combination with anti-PD-1 antibodies and a novel formulation of bizaxofusp (MDNA55) for brain cancer treatment. The company's global IP portfolio now includes 86 granted or allowed patents, supporting their clinical pipeline in oncology and autoimmune diseases.
Medicenna Therapeutics (OTCQX: MDNAF) ha rafforzato il suo portafoglio di proprietà intellettuale con cinque nuovi brevetti concessi per le sue piattaforme Superkine IL-2 e IL-4. I brevetti, che scadranno tra il 2033 e il 2040, coprono composizione, formulazione, combinazione, utilizzo e applicazioni terapeutiche nei principali mercati globali.
I brevetti chiave includono la protezione per MDNA11 in combinazione con anticorpi anti-PD-1 e una nuova formulazione di bizaxofusp (MDNA55) per il trattamento del cancro al cervello. Il portafoglio globale di proprietà intellettuale dell'azienda comprende ora 86 brevetti concessi o approvati, a supporto del loro pipeline clinico in oncologia e malattie autoimmuni.
Medicenna Therapeutics (OTCQX: MDNAF) ha fortalecido su cartera de propiedad intelectual con cinco nuevas patentes concedidas para sus plataformas Superkine IL-2 e IL-4. Las patentes, que expiran entre 2033 y 2040, cubren composición, formulación, combinación, uso y aplicaciones terapéuticas en los principales mercados globales.
Las patentes clave incluyen protección para MDNA11 en combinación con anticuerpos anti-PD-1 y una formulación novedosa de bizaxofusp (MDNA55) para el tratamiento del cáncer cerebral. La cartera global de propiedad intelectual de la compañía ahora incluye 86 patentes concedidas o aprobadas, respaldando su pipeline clínico en oncología y enfermedades autoinmunes.
Medicenna Therapeutics (OTCQX: MDNAF)는 IL-2 및 IL-4 슈퍼카인 플랫폼에 대해 새롭게 승인된 5건의 특허로 지적 재산권 포트폴리오를 강화했습니다. 이 특허들은 2033년부터 2040년까지 만료되며, 주요 글로벌 시장에서 조성, 제형, 조합, 사용 및 치료 응용을 포함합니다.
주요 특허에는 anti-PD-1 항체와의 조합으로서의 MDNA11 보호와 뇌암 치료용 bizaxofusp (MDNA55)의 새로운 제형이 포함됩니다. 회사의 글로벌 지적 재산 포트폴리오는 현재 86건의 승인된 또는 허가된 특허를 포함하며, 종양학 및 자가면역 질환 임상 파이프라인을 지원합니다.
Medicenna Therapeutics (OTCQX : MDNAF) a renforcé son portefeuille de propriété intellectuelle avec cinq nouveaux brevets délivrés pour ses plateformes Superkine IL-2 et IL-4. Les brevets, qui expirent entre 2033 et 2040, couvrent la composition, la formulation, la combinaison, l'utilisation et les applications thérapeutiques sur les principaux marchés mondiaux.
Les brevets clés incluent la protection de MDNA11 en combinaison avec des anticorps anti-PD-1 ainsi qu'une nouvelle formulation de bizaxofusp (MDNA55) pour le traitement du cancer du cerveau. Le portefeuille mondial de propriété intellectuelle de la société comprend désormais 86 brevets délivrés ou autorisés, soutenant leur pipeline clinique en oncologie et maladies auto-immunes.
Medicenna Therapeutics (OTCQX: MDNAF) hat sein geistiges Eigentumsportfolio mit fünf neu erteilten Patenten für seine IL-2- und IL-4-Superkine-Plattformen erweitert. Die Patente, die zwischen 2033 und 2040 auslaufen, umfassen Zusammensetzung, Formulierung, Kombination, Anwendung und therapeutische Einsatzmöglichkeiten in wichtigen globalen Märkten.
Zu den Schlüsselpatenten gehört der Schutz für MDNA11 in Kombination mit Anti-PD-1-Antikörpern sowie eine neuartige Formulierung von bizaxofusp (MDNA55) zur Behandlung von Hirntumoren. Das globale IP-Portfolio des Unternehmens umfasst nun 86 erteilte oder zugelassene Patente, die ihre klinische Pipeline in Onkologie und Autoimmunerkrankungen unterstützen.
- Five new patents granted across major global markets
- Patent protection extends to 2033-2040, with potential extensions
- Key coverage obtained for MDNA11 combination therapy with anti-PD1 antibodies
- Commercial exclusivity secured for bizaxofusp in brain cancer treatment
- Expanded IP portfolio now includes 86 granted or allowed patents
- Some patents are in-licensed or co-owned rather than fully owned by Medicenna
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp
TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced grant of five patents covering the Company’s IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna’s intellectual property (IP) position across key markets and further support the Company’s lead clinical and preclinical programs.
The newly granted patents cover composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines. Newly granted patents span major markets, with anticipated expiration dates ranging from 2033 to 2040 depending on the specific case and local rules, without accounting for any potential extensions.
Patents granted include:
- U.S. Patent No. 12,338,269 B2 – IL-2 Superagonists in Combination with Anti-PD-1 Antibodies.
Also granted in Australia and Japan and allowed in Canada with another divisional application allowed in Japan. [Medicenna Owned] - U.S. Patent No. 12,274,735 – IL-4 Fusion Formulation for Treatment of CNS Tumors. Also granted in Switzerland, Germany, France, and United Kingdom and allowed in Australia. [Medicenna Owned]
- U.S. Patent No. 12,187,771 – Method of Producing Th9 T Cells. Also granted in Switzerland, Germany, France, United Kingdom, India, and Japan. [In-licensed from Stanford]
- U.S. Patent No. 12,202,873 – Superagonists, Partial Agonists and Antagonists of IL-2. Also granted in Switzerland, China, Germany, France, United Kingdom, India, and Japan and allowed in Canada with another divisional application allowed in Japan. [In-licensed from Stanford]
- European Patent No. 3049525 – IL-4 Receptor-binding Fusion Proteins and Uses Thereof. Also granted in India, Japan and United States and allowed in Canada. [Co-owned with NIH]
“These newly granted and allowed patents not only expand the breadth and depth of our intellectual property portfolio but also enhance the long-term commercial potential of our Superkine programs,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “Notably, the patent covering IL-2 superagonists in combination with anti-PD1 antibodies provides important coverage for MDNA11, which is being evaluated in the ongoing Phase 1/2 ABILITY-1 study, reinforcing both the clinical rationale and commercial potential. Furthermore, protection granted to a novel formulation of bizaxofusp (MDNA55), used in the Phase 2b recurrent glioblastoma clinical trial, solidifies its commercial exclusivity for treatment of brain cancers as we pursue potential partnering of this Phase 3 ready asset. By strengthening long-term protection for our proprietary IL-2 and IL-4 assets across key jurisdictions, we are laying the foundation for durable competitive advantage and sustained shareholder value. We look forward to sharing additional clinical data from the ABILITY-1 clinical trial during the balance of this calendar year.”
Medicenna’s global IP portfolio now comprises 86 granted or allowed patents, supporting a robust and diverse clinical pipeline.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook, intellectual property protection, clinical and commercial potential, competitive position and shareholder value creation or or other statements that are not historical facts. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
ir@medicenna.com
FAQ
What new patents did Medicenna (MDNAF) receive in July 2025?
How long will Medicenna's new patent protection last?
What is the significance of MDNA11's patent protection for Medicenna?
How many total patents does Medicenna now have in its portfolio?
What markets are covered by Medicenna's new patents?
